Real-World, First-Line Osimertinib Treatment in Epidermal Growth Factor Receptor Mutation-Positive (EGFRm) Advanced NSCLC

被引：0
|
作者：
Nieva, J. [1 ]
Griesinger, F. [2 ]
Kim, Y. [3 ]
Cohen, A. [4 ,5 ]
Horvat, P. [6 ]
Lu, S. [7 ]
Taylor, A. [8 ]
Yu, N. [8 ]
Sawyer, W. [8 ]
Shenolikar, R. [8 ]
Shaw, S. [8 ]
机构：
[1] Univ Southern Calif, Norris Canc Ctr, Los Angeles, CA 90007 USA
[2] Pius Hosp Oldenburg, D-26121 Oldenburg, Germany
[3] Kyoto Univ, Grad Sch Med, Kyoto, Japan
[4] Flatiron Hlth Inc, New York, NY 10013 USA
[5] NYU, Sch Med, New York, NY USA
[6] Iqvia, Real World Solut, Emea Data Sci Hub, London, England
[7] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai, Peoples R China
[8] Astrazeneca, Cambridge, England
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 03期
关键词：
osimertinib; non-small cell lung cancer; Real-world evidence;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P76.66
引用
收藏
页码：S616 / S617
页数：2
相关论文
共 50 条
  • [1] Real-world, first-line Osimertinib treatment in epidermal growth factor receptor mutation-positive (EGFRm) advanced NSCLC
    Griesinger, F.
    Nieva, J.
    Kim, Y. -H
    Cohen, A.
    Horvat, P.
    Lu, S.
    Taylor, A.
    Yu, N.
    Sawyer, W.
    Shenolikar, R.
    Shaw, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 254 - 254
  • [2] Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT)
    Sakata, Yoshihiko
    Sakata, Shinya
    Oya, Yuko
    Tamiya, Motohiro
    Suzuki, Hidekazu
    Shibaki, Ryota
    Okada, Asuka
    Kobe, Hiroshi
    Matsumoto, Hirotaka
    Yokoi, Takashi
    Sato, Yuki
    Uenami, Takeshi
    Saito, Go
    Tsukita, Yoko
    Inaba, Megumi
    Ikeda, Hideki
    Arai, Daisuke
    Maruyama, Hirotaka
    Hara, Satoshi
    Tsumura, Shinsuke
    Morinaga, Jun
    Sakagami, Takuro
    EUROPEAN JOURNAL OF CANCER, 2021, 159 : 144 - 153
  • [3] Real-world dose adjustment study of first-line afatinib in pts with EGFR mutation-positive (EGFRm plus ) advanced NSCLC.
    Halmos, Balazs
    Tan, Eng-Huat
    Lee, Min Ki
    Foucher, Pascal
    Hsia, Te-Chun
    Hochmair, Maximilian J.
    Griesinger, Frank
    Hida, Toyoaki
    Kim, Edward S.
    Melosky, Barbara L.
    Maerten, Angela
    Costa, Enric Carcereny
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [4] Drug-Related Pneumonitis Induced by Osimertinib as First-Line Treatment for Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer A Real-World Setting
    Sato, Yuki
    Sumikawa, Hiromitsu
    Shibaki, Ryota
    Morimoto, Takeshi
    Sakata, Yoshihiko
    Oya, Yuko
    Tamiya, Motohiro
    Suzuki, Hidekazu
    Matsumoto, Hirotaka
    Yokoi, Takashi
    Hashimoto, Kazuki
    Kobe, Hiroshi
    Hino, Aoi
    Inaba, Megumi
    Tsukita, Yoko
    Ikeda, Hideki
    Arai, Daisuke
    Maruyama, Hirotaka
    Hara, Satoshi
    Tsumura, Shinsuke
    Sakata, Shinya
    Fujimoto, Daichi
    CHEST, 2022, 162 (05) : 1188 - 1198
  • [5] The cost-effectiveness of dacomitinib in first-line treatment of advanced/metastatic epidermal growth factor receptor mutation-positive non-small-cell lung cancer (EGFRm NSCLC) in Sweden
    Nilsson, Fredrik O. L.
    Gal, Peter
    Houisse, Ivan
    Ivanova, Jasmina I.
    Asanin, Sandra T.
    JOURNAL OF MEDICAL ECONOMICS, 2021, 24 (01) : 447 - 457
  • [6] Phase IV trial of afatinib followed by osimertinib versus osimertinib alone as first-line treatment in patients (pts) with advanced EGFR mutation-positive (EGFRm plus ) NSCLC
    Wehler, T.
    Wehler, B.
    Atmaca-Dirik, H.
    Schulz, C.
    Grohe, C.
    Topsch, J.
    Ehrlich, A.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S800 - S801
  • [7] Sequential treatment with afatinib and osimertinib in real-world patients with EGFR mutation-positive advanced NSCLC: the GioTag study
    Hochmair, M.
    Cufer, T.
    Morabito, A.
    Hao, D.
    Yang, C.
    Soo, R.
    Yang, J. C.
    Gucalp, R. Rasim
    Halmos, B.
    Wang, L.
    Golembesky, A.
    Maerten, A.
    O'Byrne, K.
    LUNG CANCER, 2019, 127 : S37 - S37
  • [8] Sequential treatment with afatinib and osimertinib in real-world patients with EGFR mutation-positive advanced NSCLC: the GioTag study
    Hochmair, M.
    Cufer, T.
    Morabito, A.
    Hao, D.
    Yang, C. Ta
    Soo, R.
    Yang, J.
    Gucalp, R.
    Halmos, B.
    Wang, L.
    Golembesky, A.
    Maerten, A.
    O'Byrne, K.
    LUNG CANCER, 2019, 127 : S59 - S60
  • [9] The Whole Picture of First-Line Osimertinib for EGFR Mutation-Positive Advanced NSCLC: Real-World Efficacy, Safety, Progression Pattern, and Posttreatment Therapy (Reiwa Study)
    Watanabe, Kageaki
    Hosomi, Yukio
    Naoki, Katsuhiko
    Nakahara, Yoshiro
    Tsukita, Yoko
    Matsumoto, Hirotaka
    Yoh, Kiyotaka
    Fujisaka, Yasuhito
    Takahashi, Satoshi
    Takata, Saori
    Usui, Kazuhiro
    Kishi, Kazuma
    Naka, Go
    Tamano, Shu
    Uemura, Kohei
    Kunitoh, Hideo
    JTO CLINICAL AND RESEARCH REPORTS, 2024, 5 (11):
  • [10] Afatinib followed by osimertinib in patients with EGFR mutation-positive (EGFRm plus ) advanced NSCLC: Updated data from the GioTag real-world study
    Hochmair, M. J.
    Morabito, A.
    Hao, D.
    Yang, C-T.
    Soo, R.
    Yang, J. C-H.
    Gucalp, R.
    Halmos, B.
    Wang, L.
    Golembesky, A.
    Maerten, A.
    Cufer, T.
    ANNALS OF ONCOLOGY, 2019, 30
12345